Business Description
Theriva Biologics Inc
NAICS : 325412
SIC : 2834
ISIN : US87164U1025
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 10.76 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.1 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 36.8 | |||||
3-Year EPS without NRI Growth Rate | 44.3 | |||||
3-Year FCF Growth Rate | 42.9 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.94 | |||||
9-Day RSI | 45.86 | |||||
14-Day RSI | 45.49 | |||||
6-1 Month Momentum % | 9.95 | |||||
12-1 Month Momentum % | -32.8 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.07 | |||||
Quick Ratio | 4.07 | |||||
Cash Ratio | 3.44 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -80.3 | |||||
Shareholder Yield % | -8.3 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -38.8 | |||||
ROA % | -28.5 | |||||
ROIC % | -64.04 | |||||
ROC (Joel Greenblatt) % | -1012.9 | |||||
ROCE % | -38.05 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.19 | |||||
Price-to-Tangible-Book | 0.63 | |||||
EV-to-EBIT | 0.52 | |||||
EV-to-EBITDA | 0.52 | |||||
EV-to-FCF | 0.58 | |||||
Price-to-Net-Current-Asset-Value | 0.79 | |||||
Price-to-Net-Cash | 0.93 | |||||
Earnings Yield (Greenblatt) % | 192.31 | |||||
FCF Yield % | -266.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Theriva Biologics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.075 | ||
Beta | 1.06 | ||
Volatility % | 68.77 | ||
14-Day RSI | 45.49 | ||
14-Day ATR (€) | 0.020434 | ||
20-Day SMA (€) | 0.3834 | ||
12-1 Month Momentum % | -32.8 | ||
52-Week Range (€) | 0.323 - 1.28 | ||
Shares Outstanding (Mil) | 17.15 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Theriva Biologics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Theriva Biologics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Theriva Biologics Inc Frequently Asked Questions
What is Theriva Biologics Inc(FRA:SFY)'s stock price today?
When is next earnings date of Theriva Biologics Inc(FRA:SFY)?
Does Theriva Biologics Inc(FRA:SFY) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |